NSE
Glenmark Pharmaceuticals LimitedGLENMARK
Glenmark Pharmaceuticals is a research-led branded-generics company.
| Key products | Dermatology, respiratory and oncology generics & specialty; APIs. |
|---|---|
| Geography | India, US, Europe, emerging markets. |
| Competitors | Cipla, Sun Pharma, Lupin. |
AI-generated overview — verify before relying on it.
Net institutional flow
No institutional deals
Institutional buyers
0 in / 0 out
High-impact filings
0 · tilt Neutral
Next corporate action
Interim Dividend - Rs 2.50 Per Share
ex 2025-10-03
| # | Company | Inst. flow ₹Cr | Deals | Hi-impact | Filing mom. | Buzz | News |
|---|---|---|---|---|---|---|---|
| 1 | ALKEM | +₹1,013.7 Cr | 13 | — | — | -2 | 6 |
| 2 | GLENMARKThis | — | — | — | — | — | — |
| 3 | CIPLA | — | — | — | — | +19 | 44 |
| 4 | DRREDDY | — | — | — | — | +20 | 46 |
| 5 | SUNPHARMA | — | — | — | — | +15 | 45 |
| 6 | TORNTPHARM | — | — | — | — | — | — |
| 7 | LUPIN | — | — | — | — | — | — |
| 8 | ZYDUSLIFE | — | — | 1 | +1 | — | — |
| 9 | AUROPHARMA | — | — | — | — | — | — |
Ranked by net institutional flow (buys − sells, ₹Cr). Filing momentum = bullish − bearish filings; Buzz = news+social sentiment. Curate peers in the company admin.
- 2026-06-17FilingGlenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated Jun 17, 2026, titlePress Release
- 2026-06-11FilingGlenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated Jun 11, 2026, titlePress Release
- 2026-06-09FilingGlenmark Pharmaceuticals Limited has informed the Exchange about Investor PresentationInvestor Call
- 2025-10-03ActionInterim Dividend - Rs 2.50 Per ShareDividend
- 2025-09-15ActionDividend - Rs 2.50 Per ShareDividend
- 2025-07-11BulkBUY · ₹328.1 CrGRAVITON RESEARCH CAPITAL LLP
- 2025-07-11BulkSELL · ₹328.3 CrGRAVITON RESEARCH CAPITAL LLP
- 2025-07-11NetDay net −₹0.2 Cr
- 2025-03-25BlockBUY · ₹39.5 CrINTEGRATED CORE STRATEGIES (ASIA) PTE. LTD.
- 2025-03-25BlockSELL · ₹39.5 CrUBS AG
- 2025-01-23BlockBUY · ₹101.4 CrUBS AG
- 2025-01-23BlockSELL · ₹101.4 CrUBS PRINCIPAL CAPITAL ASIA LIMITED
- 2024-09-13ActionDividend - Rs 2.50 Per ShareDividend
Merged from deals, filings, corporate actions and news — newest first. Compact rolls each day up to net flow + counts. Scope with the range above.
Filings that matter
- 2Press ReleaseNeutral
a press release dated Jun 17, 2026, titled "Glenmark Pharmaceuticals Inc., USA launches Methylene Blue Injection USP, 50 mg/10 mL (5 mg/mL) Single-Dose Vial".
Source PDF → - 2Press ReleaseNeutral
a press release dated Jun 11, 2026, titled "Glenmark Launches Winlevi® (clascoterone) 10 mg/g cream in Key European Markets for the Treatment of Acne Vulgaris".
Source PDF → - 3
6 deals · 2025-01-23 → 2025-07-11
| Date | Counterparty | Type | Side | Value |
|---|---|---|---|---|
| 2025-07-11 | GRAVITON RESEARCH CAPITAL LLP | Prop / churn | BUY | ₹328.1 Cr |
| 2025-07-11 | GRAVITON RESEARCH CAPITAL LLP | Prop / churn | SELL | ₹328.3 Cr |
| 2025-03-25 | INTEGRATED CORE STRATEGIES (ASIA) PTE. LTD. | HNI / other | BUY | ₹39.5 Cr |
| 2025-03-25 | UBS AG | HNI / other | SELL | ₹39.5 Cr |
| 2025-01-23 | UBS AG | HNI / other | BUY | ₹101.4 Cr |
| 2025-01-23 | UBS PRINCIPAL CAPITAL ASIA LIMITED | HNI / other | SELL | ₹101.4 Cr |
6 deals in the selected window — corporate actions are scoped to the same period. ~2 years of history available.
Results & transcripts
Financial results
None yet.
News & chatter on GLENMARK
RSS News
0No recent news.
Google News RSS — links open the source.
Investdesk
0No articles yet.
Our coverage.
No Reddit chatter.
r/ posts mentioning the company.
Twitter / X
0No posts.
Posts mentioning the company.